Three timepoint perioperative CEA levels are a prognostic factor for recurrence after adjuvant chemotherapy in patients with Stage II and III colorectal cancer

Three timepoint perioperative CEA levels are a prognostic factor for recurrence after adjuvant chemotherapy in patients with Stage II and III colorectal cancer

Abstract Aim To investigate the relationship between the three timepoint perioperative CEA (ttpCEA) calculated at three timepoints and recurrence during the perioperative period in Stage II and III colorectal cancer (CRC) patients. Methods We performed a multi‐institutional retrospective analysis of...

Full description

Saved in:
Bibliographic Details
Main Authors: Shodai Mizuno, Kohei Shigeta, Ryosuke Hara, Kyoko Sakamoto, Jumpei Nakadai, Hideo Baba, Hiroto Kikuchi, Yoko Adachi, Takehiro Shimada, Hirofumi Suzumura, Kiyoaki Sugiura, Shimpei Matsui, Ryo Seishima, Koji Okabayashi, Yuko Kitagawa
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Annals of Gastroenterological Surgery
Subjects:
adjuvant chemotherapy
CEA
colorectal cancer
multi‐institutional study
recurrence
Online Access:https://doi.org/10.1002/ags3.12886
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim To investigate the relationship between the three timepoint perioperative CEA (ttpCEA) calculated at three timepoints and recurrence during the perioperative period in Stage II and III colorectal cancer (CRC) patients. Methods We performed a multi‐institutional retrospective analysis of patients with Stage II and III CRC who underwent surgery and adjuvant chemotherapy from 2010 to 2020. Patient data from three facilities were used as training data, and data from three other facilities were used as validation data. The primary endpoint was the time to recurrence (TTR). Results A total of 538 patients were included for the training data. To validate the feasibility of ttpCEA, 329 patients were included for the validation data. Training data patients were categorized as ttpCEA low (n = 365) and ttpCEA high (n = 173). The 5‐y TTR was significantly greater in the ttpCEA‐low subgroup than in the ttpCEA‐high subgroup (84.3% vs. 69.6%, respectively; p < 0.001). Validation data patients were categorized as ttpCEA low (n = 221) and ttpCEA high (n = 108). The 5‐y TTR was significantly greater in the ttpCEA‐low subgroup than in the ttpCEA‐high subgroup (82.9% vs. 68.7%, respectively; p = 0.003). Conclusion The ttpCEA calculated from perioperative CEA levels at different timepoints was a prognostic factor for recurrence in Stage II and III CRC patients who underwent adjuvant chemotherapy according to both the training and validation data.
ISSN:2475-0328

Similar Items